Évaluation de l’efficacité du secukinumab (blanchiment des lésions et données patients) pendant 2 ans dans le psoriasis modéré à sévère : étude CLEAR
Andrew Blauvelt(Veterans Health Administration), Diamant Thaçi(University of Lübeck), Kristian Reich(Dermatologikum Hamburg), P. Celérier(Centre Hospitalier de La Rochelle), Külli Kingo(Tartu University Hospital), M. Beylot‐Barry(Université de Bordeaux), Andreas Pinter(Goethe University Frankfurt), A. Lacombe(Novartis (Switzerland)), Michael Ziv(Emek Medical Center), Lucie Martin(Novartis (France)), Ronald Vender(Dermatrials Research), Vaishali Bhosekar(Novartis (India)), Tsen‐Fang Tsai(National Taiwan University Hospital), I. Gilloteau(Novartis (Switzerland)), S. Xia(Novartis (China)), Adriana Guana(Novartis (Switzerland)), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), M. Ruer‐Mulard, F. Vanaclocha(Research Institute Hospital 12 de Octubre), L. Puig(Universitat Autònoma de Barcelona), Stephen K. Tyring(Center for Clinical Studies)
Cited by 0
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842